Calimmune picks up $15 mln Series B
Tucson, Arizona-based gene therapy company Calimmune Inc has closed $15 million in Series B funding. The investors included Alexandria Venture Investments, RA Capital Healthcare Fund LP and Translational Accelerator LLC.
27 May 2015•3 mins read
